American Society of Hematology Annual Meeting

Dose Reduction of Xpovio Improves Safety and Optimizes Patient Outcomes in Myeloma

December 10th 2021, 8:00pm

Video

In recent trial results, a dose reduction of Xpovio (selinexor) was associated with longer progression-free survival and duration of response while also reducing side effects in patients with multiple myeloma.

Early Use of Fixed-Duration Venclexta-Rituxan Combo in Patients with Relapsed/Refractory CLL Effective, And Does Not Compromise Subsequent Therapy Response in Patients Who Need Retreatment

December 14th 2020, 4:00pm

Article

More than half of the patients (66.7%) in the Venclexta and Rituxan arm who went on to receive subsequent Venclexta-based treatments experienced a partial response or partial nodal response to the therapy.

Venclexta Added to Novel Combination Therapy Elicits High Responses in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

December 14th 2020, 2:00pm

Article

Among 27 patients with relapsed/refractory chronic lymphocytic leukemia patients who completed all 12 cycles of the triplet therapy, 100% of patients had a complete or partial response to the treatment—with 41% achieving a complete response.

Novel Combination Therapy Contributes to Additional Progression-Free Survival Benefit Compared With Chemoimmunotherapy in Patients with CLL

December 9th 2020, 2:00pm

Article

The combination of ublituximab and umbralisib, two novel compounds, was able to safely prolong progression-free survival with low rates of toxicities in patients with chronic lymphocytic leukemia compared with standard of care chemoimmunotherapy regardless of prior treatment.

Calquence Use Associated With Limited Heart Toxicities in Patients With Chronic Lymphocytic Leukemia

December 8th 2020, 10:00pm

Article

At a median follow-up of 25.9 months, 17% of the patient population who received Calquence monotherapy experienced a cardiac toxicity of any severity, which led to treatment discontinuation in only seven patients.

Investigational CAR-T Cell Therapy Lisocabtagene Maraleucel Shows Durable Responses in Patients with Relapsed/Refractory CLL/SLL

December 8th 2020, 7:00pm

Article

The early study of the investigational CAR-T cell therapy lisocabtagene maraleucel shows how patients with relapsed/refractory CLL/SLL may have a viable new treatment option.

Significant Number of Patients With Blood Cancers Deal With Depression or Anxiety Before or After Diagnosis, Highlighting ‘Critical’ Need for Mental Health Screening and Management

December 8th 2020, 4:00pm

Article

This data, according to a resident physician at Brigham and Women’s Hospital, highlights the need for systematic mental health screening and management for individuals with blood cancers.

Long-Term Data of Imbruvica-Rituxan Combo in Waldenstrom’s Macroglobulinemia Demonstrates ‘Major Step Forward’

December 8th 2020, 2:15pm

Video

In an interview with CURE®, a Waldenstrom’s macroglobulinemia expert discusses the long-term benefits of the targeted combination of Imbruvica and Rituxan.

Patients With Aggressive Lymphomas Experience Major Quality of Life Improvements 1 Year After Diagnosis

December 7th 2020, 10:00pm

Article

Patients with aggressive lymphomas experienced sharp increases in quality of life from time of diagnosis until one year later and continued to see improvements for almost a decade.

Imbruvica-Based Treatment Elicited Long-Term Survival Benefits in Subset of Patients With CLL Who Historically Have Poor Outcomes

December 7th 2020, 8:00pm

Video

Imbruvica treatment in patients with chronic lymphocytic leukemia whose disease expressed a certain mutation elicited sustained efficacy over a median follow-up of four years, according to data from a long-term analysis.